Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: DataM Intelligence | PRODUCT CODE: 1268942

Cover Image

PUBLISHER: DataM Intelligence | PRODUCT CODE: 1268942

Global Live Attenuated Vaccines Market - 2023-2030

PUBLISHED:
PAGES: 195 Pages
DELIVERY TIME: 2 business days
SELECT AN OPTION
PDF & Excel (Single User License)
USD 4350
PDF & Excel (Multiple User License)
USD 4850
PDF & Excel (Enterprise License)
USD 7850

Add to Cart

Market Overview

The global live attenuated vaccines market size reached US$ 7,190.7 million in 2022 and is projected to witness lucrative growth by reaching up to US$ 15,520.9 million by 2030. The market is expected to exhibit a CAGR of 10.3% during the forecast period (2023-2030).

The live attenuated vaccines market has seen significant growth in recent years due to the increasing demand for effective and safe vaccines against various infectious diseases, worldwide. These vaccines are known for their ability to provide long-lasting immunity with a single dose, as they are capable of replicating in the body and inducing a strong immune response.

Moreover, the COVID-19 pandemic highlighted the importance of vaccination in preventing the spread of infectious diseases, which further boosts the live attenuated vaccines market growth.

Market Dynamics

Growing awareness about vaccination driving the live attenuated vaccines market growth

There is an increasing awareness among individuals, communities, and healthcare providers about the importance of vaccination in preventing infectious diseases. Vaccination campaigns, education programs, and promotional activities by governments, non-governmental organizations (NGOs), and healthcare agencies are creating awareness about the benefits of vaccines, including live attenuated vaccines. This increased awareness is driving the demand for live attenuated vaccines as a preventive measure against infectious diseases.

Many governments around the world are actively promoting vaccination programs as a key public health intervention. Governments are implementing various initiatives, such as national immunization programs, vaccination mandates, and funding for vaccine research and development, to improve vaccine coverage rates and protect their people from infectious diseases. These favorable government initiatives are providing a supportive environment for the growth of the live attenuated vaccines market.

Regulatory challenges will hamper the growth of the market

The development and distribution of vaccines are subject to stringent regulatory requirements and approvals from regulatory agencies such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and other national regulatory bodies. Meeting these regulatory requirements can be time-consuming and costly, and failure to obtain regulatory approvals can significantly impact the availability and marketability of live attenuated vaccines. Regulatory challenges may act as a restraint to the growth of the live attenuated vaccines market.

COVID-19 Impact Analysis

The urgency and global impact of the COVID-19 pandemic have accelerated the research and development of vaccines, including live attenuated vaccines, to combat the virus. This has led to increased investment and efforts in vaccine development, which may have positive spillover effects on the live attenuated vaccines market as well.

The COVID-19 pandemic has heightened public awareness about the importance of vaccines in preventing infectious diseases. This increased awareness and emphasis on vaccination may lead to greater acceptance and uptake of vaccines, including live attenuated vaccines, in the general population, which can positively impact the market.

Russia Ukraine Conflict Analysis

The ongoing conflict between Russia and Ukraine may have potential implications for the live attenuated vaccines market, particularly in the region directly affected by the conflict. The conflict may disrupt the transportation and distribution of live attenuated vaccines, leading to potential shortages or delays in vaccine availability. This could impact the ability of healthcare systems in the affected region to administer vaccines and may result in decreased demand for live attenuated vaccines.

The conflict may lead to the displacement of population, damage to healthcare infrastructure, and disruption of healthcare services, including vaccination programs. This could result in decreased access to healthcare, including live attenuated vaccines, for those affected by the conflict, leading to reduced demand and uptake of vaccines.

Segment Analysis

The global live attenuated vaccines market is segmented based on type, development, end user and region.

Owing to advanced techniques, the viral vaccine segment drives the market growth

The viral vaccine segment of the global live attenuated vaccine market was valued at US$ 4,059.9 million in 2022 and is estimated to grow at a CAGR of 10.5% over the forecast period to reach US$ 8,839.2 million by 2030. Viral vaccines are biological preparations that stimulate the immune system to produce an immune response against specific viruses, helping to prevent or reduce the severity of viral diseases. The viral vaccine segment encompasses vaccines for a wide range of viral diseases, including but not limited to influenza, measles, mumps, rubella, hepatitis, human papillomavirus (HPV), polio, and COVID-19.

In recent years, due to various factors such as increasing awareness about the benefits of vaccination, rising global population, growing burden of viral diseases, advancements in vaccine technology, and increased investment in research and development, the market has witnessed growth. Vaccination is considered one of the most cost-effective ways to prevent infectious diseases, and it has led to the eradication or significant reduction of many viral diseases that were once major global health threats. Overall, the viral vaccine segment plays a crucial role in public health by providing effective tools to prevent the spread of viral diseases and protect global populations from infectious diseases.

Geographical Analysis

The strong presence of major players and increased awareness about the use of eco-friendly vaccine types

The North America live attenuated vaccines market is driven by several factors, including the high prevalence of infectious diseases, government immunization programs, increasing awareness about the importance of vaccination, and advancements in vaccine research and development. Live attenuated vaccines have been widely used in North America for the prevention of diseases such as measles, mumps, rubella, influenza, yellow fever, and rotavirus, among others.

Competitive Landscape

The live attenuated vaccines market is highly competitive with the presence of a large number of existing major players and small vendors. Some of the major players in the global live attenuated vaccines market include Merck & Co., Inc., GlaxoSmithKline plc, Pfizer Inc., Sanofi, Astellas Pharma, CSL Limited, Serum Institute of India Pvt. Ltd., BioDiem, AstraZeneca, Emergent BioSolutions Inc., and Vivaldi Biosciences Inc., among others.

Why Purchase the Report?

  • To visualize the global live attenuated vaccines market segmentation based on type, development and region and understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of live attenuated vaccines market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Type mapping available as Excel consisting of key Types of all the major players.

The global live attenuated vaccines market report would provide approximately 54 tables, 46 figures and 195 pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies
Product Code: PH2094

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Type
  • 3.2. Snippet by Development
  • 3.3. Snippet by End User
  • 3.4. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Rising government, and private research and development funding
    • 4.1.2. Restraints
      • 4.1.2.1. Regulatory challenges will hamper the growth of the market
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Before COVID-19 Scenario
    • 6.1.2. Present COVID-19 Scenario
    • 6.1.3. Post COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturer's Strategic Initiatives
  • 6.6. Conclusion

7. By Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 7.1.2. Market Attractiveness Index, By Type
  • 7.2. Viral*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Bacterial

8. By Development

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Development
    • 8.1.2. Market Attractiveness Index, By Development
  • 8.2. Tissue Culture*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
    • 8.2.3. Live Animals
    • 8.2.4. Embryonated Eggs

9. By End User

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 9.1.2. Market Attractiveness Index, By End User
  • 9.2. Hospitals and Clinics*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
    • 9.2.3. Research Institutes
    • 9.2.4. Other

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Development
    • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. The U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Development
    • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. The U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Development
    • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia-Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Development
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia-Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Development
    • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

  • 12.1. GlaxoSmithKline plc*
    • 12.1.1. Company Overview
    • 12.1.2. Type Portfolio and Description
    • 12.1.3. Financial Overview
    • 12.1.4. Key Developments
  • 12.2. Merck & Co., Inc.
  • 12.3. Daiichi Sankyo Company
  • 12.4. Sanofi
  • 12.5. Valneva SE
  • 12.6. Vivaldi Biosciences Inc.
  • 12.7. Serum Institute of India Pvt Ltd.
  • 12.8. BioDiem
  • 12.9. Polymun Scientific
  • 12.10. Emergent BioSolutions Inc.

LIST NOT EXHAUSTIVE

13. Appendix

  • 13.1. About Us and Services
  • 13.2. Contact Us
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!